EC Number   |
|---|
   3.2.1.114 | - |
| 3.2.1.114 | by hanging-drop vapor diffusion method, GMII in complex with inhibitors di-epi-swainsonine and 8-epi-lentiginosine, both adopt a 3C6/E7 conformation, water molecule substructure in the active site plays a significant role in dictating inhibitory activity |
| 3.2.1.114 | crystal structure of enzyme with bound inhibitors kifunensine, swainsonine and 1-deoxymannojirimycin |
| 3.2.1.114 | enzyme in complex with inhibitors mannostatin A, N-benzyl mannostatin A, and 1-deoxyaminocyclopentitetrol, crystal growth overnight of enzyme solved in phosphate buffered reservoir solution, crystals are soaked for 3-6 h in 10 mM ligand solution, co-crystallization in Tris buffer without phosphate washing, X-ray diffraction structure determination and analysis, molecular modelling and structure simulation, overview |
| 3.2.1.114 | enzyme with bound unhibitors, X-ray diffraction structure determination and analysis |
| 3.2.1.114 | GMII complexed with inhibitors (2R,3R,4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3,4-diol, (2R,3R,4S)-2-([[(1S)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3,4-diol, and (2R,3R,4S,5R)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-5-methylpyrrolidine-3,4-diol, to 1.30-1.45 A resolution |
| 3.2.1.114 | hanging drop vapor diffusion |
| 3.2.1.114 | in complex with inhibitor mannostatin A and its derivatives. The interaction with the backbone carbonyl of residue R876 is crucial to the high potency of the inhibitor and enhanced by the hydrophobic interaction between the thiomethyl group and an aromatic pocket vivinal to the cleavage site |
| 3.2.1.114 | in complex with inhibitors (3R,4R,5R)-3,4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidin-2-one and (3R,4R,5R)-3,4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1-methylpyrrolidin-2-one, to 1.08 A and 1.74 A resolution, respectively |
| 3.2.1.114 | in complex with inhibitors mannoimidazole, glucoimidazole, N-octyl-6-epi-valienamine, gluco-hydroxyiminolactam, and [[(3S,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)piperidin-2-ylidene]amino] N-(4-chlorophenyl)carbamate |
